Abstract
Diabetes mellitus has a world death rate of 1.6 million (2016) of which Type 2 diabetes mellitus (T2DM) accounts for ∼90% of all cases. Early detection of T2D high-risk patients can reduce the incidence of the disease through a change in lifestyle, diet, or medication. Since lower socio-demographics layers are more susceptible to T2D and might have limited resources for laboratory testing, there is a need for accurate prediction models based on non-laboratory parameters. Here, we analysed data of 44,879 non-diabetic, UK-Biobank participants at the ages 40-65 within a time frame of 7.3±2.3 years. We devise a non-laboratory prediction model for T2DM onset probability using sex, age, weight, height, waist, hips-circumferences, Waist-Hips Ratio (WHR) and Body-Mass Index (BMI). This model achieved an Area Under the Receiver Operating Curve (auROC) of 0.82 (0.79-0.84 95% CI) and an odds ratio (OR) between the top and lowest prevalence deciles of x42 (33-49). The logistic regression top predictive parameters are WHR with OR of 0.67 (0.49-0.88 95%CI) followed by BMI with OR of 0.53 (0.26-0.79). We further analyse the contribution of laboratory-based parameters and devise a blood-test model based on only five blood tests. In this model, we are using age, sex, Glycated Hemoglobin (HbA1c%), reticulocyte count, Gamma Glutamyl-Transferase, Triglycerides, and HDL cholesterol to predict T2D onset more accurately. This model achieves an auROC of 0.89 (0.87-0.92) and a deciles’ OR of x59 (27-75). We also analysed a model that included genotyping data and other environmental factors and found that it did not provide further benefit over the five-blood-tests model. Our models outperform the current state of the art, non-laboratory, Finnish Diabetes Risk Score and the German Diabetes Risk Score, trained on our data, achieving auROC of 0.74 (0.7-0.77) and 0.63 (0.59-0.67), respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
E.S. is supported by the Crown Human Genome Center, by D. L. Schwarz, J. N. Halpern and L. Steinberg, and by grants funded by the European Research Council and the Israel Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
01/03/2020 Title of the project: COPY from protocol: 149-1 - Development of models relating genetics, diet, lifestyle, and clinical outcomes (945-1) Submitted by: Eran Segal on 01/03/2020 Dear Eran Segal, This is to certify that Weizmann Institutional Review Board (IRB) reviewed the above research project and approved it for execution at the Weizmann Institute of Science. The certificate of approval expires on 01/03/2023 Sincerely yours Prof. Yosef Shaul, Head Weizmann IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The UKB data are available through the UK Biobank Access Management System https://www.ukbiobank.ac.uk/
